Wipro GE Healthcare unveiled a significant investment plan of over $1 billion (approximately Rs 8000 crore) over the next five years in manufacturing output and local research and development (R&D). This strategic initiative aims to enhance Wipro GE Healthcare's local manufacturing capabilities to meet the rising demand in both domestic and international markets and to reinforce the organization's supply chain resilience.
As part of this investment, Wipro GE Healthcare will expand its 'Made in India' portfolio, with products such as the PET CT Discovery IQ, which will be exported to 15 countries. Furthermore, the organization will manufacture the 'Made in India' Revolution Aspire CT, Revolution ACT, and MR breast coils for global distribution.
India ranks among the top 20 global markets for medical devices, making it a key focus area for GE HealthCare. Peter J. Arduini, president and CEO of GE HealthCare, emphasized the company's commitment to investing in India's domestic capabilities and expanding its global footprint in MedTech manufacturing and R&D. He noted that this investment aligns with GE HealthCare's strategic vision to deliver precision innovation worldwide and to accelerate India's position as a MedTech innovation and manufacturing hub.
Azim Premji, chairman of Wipro GE Healthcare, highlighted India's burgeoning healthcare industry and rapidly expanding MedTech sector. He emphasized the role of initiatives like 'Make in India' in driving the exponential growth of manufacturing capabilities in the country, thereby strengthening India's position as the MedTech hub of the world.
.jpg "Artificial Intelligence to Revolutionize Advanced Chip Design")
